GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Allurion Technologies Inc (NYSE:ALUR) » Definitions » EV-to-FCF

Allurion Technologies (Allurion Technologies) EV-to-FCF : -1.49 (As of May. 13, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Allurion Technologies EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Allurion Technologies's Enterprise Value is $97.74 Mil. Allurion Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was $-65.59 Mil. Therefore, Allurion Technologies's EV-to-FCF for today is -1.49.

The historical rank and industry rank for Allurion Technologies's EV-to-FCF or its related term are showing as below:

ALUR' s EV-to-FCF Range Over the Past 10 Years
Min: -8.54   Med: -2.3   Max: -1.33
Current: -1.49

During the past 3 years, the highest EV-to-FCF of Allurion Technologies was -1.33. The lowest was -8.54. And the median was -2.30.

ALUR's EV-to-FCF is ranked worse than
100% of 360 companies
in the Medical Devices & Instruments industry
Industry Median: 28.725 vs ALUR: -1.49

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-13), Allurion Technologies's stock price is $2.04. Allurion Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.827. Therefore, Allurion Technologies's PE Ratio for today is At Loss.


Allurion Technologies EV-to-FCF Historical Data

The historical data trend for Allurion Technologies's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Allurion Technologies EV-to-FCF Chart

Allurion Technologies Annual Data
Trend Dec21 Dec22 Dec23
EV-to-FCF
- - -2.78

Allurion Technologies Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only - - - -3.06 -2.78

Competitive Comparison of Allurion Technologies's EV-to-FCF

For the Medical Devices subindustry, Allurion Technologies's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Allurion Technologies's EV-to-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Allurion Technologies's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Allurion Technologies's EV-to-FCF falls into.



Allurion Technologies EV-to-FCF Calculation

Allurion Technologies's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=97.742/-65.588
=-1.49

Allurion Technologies's current Enterprise Value is $97.74 Mil.
Allurion Technologies's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Allurion Technologies  (NYSE:ALUR) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Allurion Technologies's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.04/-1.827
=At Loss

Allurion Technologies's share price for today is $2.04.
Allurion Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.827.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Allurion Technologies EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Allurion Technologies's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Allurion Technologies (Allurion Technologies) Business Description

Traded in Other Exchanges
N/A
Address
11 Huron Drive, Natick, MA, USA, 01760
Website
Allurion Technologies Inc is a leading medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
Executives
Omar Ishrak director 710 MEDTRONIC PKWY, MS LC300, MINNEAPOLIS MN 55432
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Krishna K. Gupta director, 10 percent owner 307 HARVARD ST, CAMBRIDGE MA 02139
Christopher J Geberth officer: Chief Financial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Michael R Davin director C/O CYNOSURE, INC., 5 CARLISLE ROAD, WESTFORD MA 01886
Larson Douglas Hudson director 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Benoit Chardon officer: Chief Commercial Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Shantanu Gaur director, officer: Chief Executive Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760
Ram Chuttani officer: Chief Medical Officer 11 HURON DRIVE, SUITE 200, NATICK MA 01760